Please assess the completion status of the following clinical trial:

Trial Title: The ONE Study M Reg Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
RECIPEINT~Inclusion Criteria:~* Chronic renal insufficiency necessitating kidney Tx~* Aged at least 18 years~* Able to commence the immunosuppressive regimen as specified~* Willing and able to participate in The ONE Study subprojects~* Signed and dated written informed consent~Exclusion Criteria:~* Patient has previously received any tissue or organ Tx~* Known contraindication to the protocol-specified treatments /medications~* HLA 0-0-0 mismatch~* PRA grade \>40% within 6 mo. prior to enrolment~* Previous desensitisation treatment~* Concomitant malignancy or history of malignancy \<5 years before study entry (excluding successfully-treated non-metastatic skin BCC or SCC)~* Significant local or systemic infection~* HIV-positive, EBV-negative or suffering chronic viral hepatitis~* CMV negative and receiving a kidney from a CMV+ donor~* Significant liver disease~* Malignant or pre-malignant haematological conditions~* Any uncontrolled condition that could interfere with study objectives~* Any condition placing the subject at undue risk~* Ongoing treatment with systemic immunosuppressive drugs at study entry~* Exposure to an investigational product during the study, or within 28 days or 5 half-lives of the product before study entry~* Female patients of child-bearing potential with a +pregnancy test~* Female patients breast-feeding or that are of child bearing potential and unwilling to use effective birth control~* Psychological, familial, sociological or geographical factors hampering compliance~* Any substance abuse or psychiatric disorder~* Patients unable to freely give informed consent~* Known IgA or IgG deficiency~* Any pro-coagulant disposition causing undue risk~* Previous history of transfusion-associated disease causing undue risk~* Conditions resulting in substantially reduced pulmonary vasculature or increased pulmonary vascular resistance. Diseases causing substantially elevated pulmonary arterial or right heart hypertrophy or dysfunction~* Known atrial or ventricular septal defects posing a risk of embolism~* Known hypersensitivity to components of the manufactured cell product~DONOR~Inclusion Criteria:~* Eligible for live kidney donation~* Aged at least 18 years~* Willing and able to provide a blood sample for The ONE Study Subproject~* Willing to provide personal and medical/biological data for the trial analysis~* Eligible for leucapheresis prior to organ donation~* Signed and dated written informed consent~Exclusion Criteria:~* Genetically identical to the prospective organ recipient at the HLA loci (0-0-0 mismatch)~* CMV-positive and donating to a CMV-negative recipient~* Exposure to an investigational product during the study, or within 28 days or 5 half-lives of the product before study entry~* Any form of substance abuse, psychiatric disorder, or other condition that, in the opinion of the Investigator, may invalidate communication with the investigator and/or designated study personnel~* Subjects unable to freely give their informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- M reg treatment (Type: EXPERIMENTAL): Donor M reg (2.5-7.5 million cells/kg) IV infused (6-7d before Tx) into recipients of a LD renal Tx. Recipients also receive prednisolone, mycophenolate mofetil and tacrolimus, as detailed below:~Prednisolone~* D 0: 500 mg IV~* D 1: 125 mg IV~* D 2 - 14: 20.0 mg/d (oral)~* Wk 3 - 4: 15.0 mg/d~* Wk 5 - 8: 10.0 mg/d~* Wk 9 - 12: 5.0 mg/d~* Wk 13 - 14: 2.5 mg/d~* Wk 15 - End: Cessation~MMF (or biologic equiv.)~* D -7 to -2: 500 mg/d (250mg 2x/d)~* D -1 to 14: 2000 mg/d~* Wk 3 - 36: 1000 mg/d~* Wk 37 - 40: 750 mg/d~* Wk 41 - 44: 500 mg/d~* Wk 45 - 48: 250 mg/d~* Wk 49 - End: Cessation NOTE: MMF tapering will only happen if a 36-Wk biopsy shows no signs of subclinical rejection or if there is no evidence of declining renal function or if the clinician has any other concern about dose reduction.~Tacrolimus (or biologic equiv.)~* ≤ 48 h pre-Tx to D 14: 3-12 ng/ml~* Wk 3 - 12: 3-10 ng/ml~* Wk 13 - 36: 3-8 ng/ml~* Wk 37 - End: 3-6 ng/ml

Based on this trial design, predict the completion outcome and termination type (if applicable).